In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech ONCY.
In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward."
Oncolytics Biotech closed on Friday at $0.42.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in